aTyr Pharma, Inc.

NASDAQ:ATYR

Biotechnology

Healthcare
$0.53 +14.23%

+$0.07 today

Market cap
$52.13M
Beta
0.54
P/E (TTM)
-0.7
EPS (TTM)
-$0.71
52W Low $0.40High $7.29

Volume 1.02M

Average 2.29M

ATYR Total Equity

Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.

aTyr Pharma, Inc.NASDAQ: ATYR

Total Equity · Q1 FY2026 · quarter ended Mar 2026

Total equity falls 22.9% from a year ago

Total equity stood at $57.74M at the end of Q1 FY2026, down 22.9% from a year earlier and down 14.2% from the prior quarter. Over 3 fiscal years it compounded at -1.9% a year.

Context

  • Total equity amounted to 72.5% of total assets at the end of Q1 FY2026, down 4.5 pp from a year earlier.
  • Total equity increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether total equity keeps falling in the next quarterly balance sheet after a -22.9% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$57.74M-14.2% QoQ
Last fiscal yearDec 2025
$67.29M-3.6% YoY
Year agoMar 2025
$74.86M-22.9% since
Total Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-22.9%——
1 year-3.6%——
3-year CAGR-1.9%——
5-year CAGR——
10-year CAGR——

Total Equity history

USD · from the balance sheet

Latest · FY2025
67.29M USD
Year-over-year change
-3.6%
4-year CAGR
-11.4%

Total Equity vs competitors

How ATYR compares with its peers on the latest reported figures

  • Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -22.9% is the 5th highest of 8, against a peer median of +54.2%.
  • Total equity amounts to 72.5% of total assets for ATYR, versus a peer median of 64.6%.
ATYR Competitors
Total Equity for ATYR and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
RLMDRelmada Therapeutics, Inc.Mar 2026$218.73M USD+874.7%-14.9%92.9%
ALXOALX Oncology Holdings Inc.Mar 2026$151.35M USD+71.4%-53.8%84.9%
ACRVAcrivon Therapeutics, Inc. Common StockMar 2026$95.52M USD-40.4%-12.9%88.6%
DTILPrecision BioSciences, Inc.Mar 2026$76.1M USD+54.2%+15.1%52.9%
ATYRaTyr Pharma, Inc.Mar 2026$57.74M USD-22.9%-1.9%72.5%
UNCYUnicycive Therapeutics, Inc.Mar 2026$37.7M USD+234.5%—58.5%
CAMPCAMP4 Therapeutics CorporationMar 2026$30.9M USD-40.1%—29.3%
HYFTMindWalk Holdings Corp.Jan 2026CA$14.98M CAD-40.4%-32.0%64.6%
Peer median (excluding ATYR) —+54.2%-14.9%64.6%

Competitors are the stored peer set for ATYR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents2.34M9.98M22.54M11.06M10.74M
Short-term Investments105.58M56.17M75.62M61.07M67.94M
Net Receivables435K11.78M2.44M1.74M873K
Inventory00000
Other Current Assets00000
Total Current Assets113.57M80.87M102.99M81.95M80.24M
Property, Plant & Equipment (Net)1.81M11.56M14.05M11.86M10.38M
Goodwill00000
Intangible Assets00000
Long-term Investments00002.24M
Tax Assets00000
Other Non-current Assets158K3.36M3.62M3.02M1.31M
Total Non-current Assets1.97M14.92M17.66M14.88M13.93M
Total Assets115.54M95.79M120.65M96.83M94.16M
Account Payables1.03M3.11M3.53M4.32M3.89M
Short-term Debt00001.47M
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities00006.81M
Total Current Liabilities6.01M13.86M16.42M14.97M15.15M
Long-term Debt00000
Deferred Tax Liabilities00001.16M
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities398K10.64M13.77M12.03M11.73M
Total Liabilities6.41M24.5M30.18M27M26.88M
Common Stock28K29K63K84K98K
Retained Earnings(372.3M)(417.63M)(468.02M)(532.05M)(606.16M)
Accumulated OCI(263K)(433K)(74K)(40K)(8K)
Other Stockholders Equity00000
Minority Interest(175K)(180K)(188K)(187K)(192K)
Total Equity109.13M71.28M90.47M69.83M67.29M
Total Debt1.38M11.53M15.1M13.28M12.03M
Net Debt(958K)1.55M(7.45M)2.23M1.29M

aTyr Pharma, Inc.

NASDAQ:ATYR

Intrinsic Alpha fair value

Locked

Current Price

$0.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.